Concerns regarding the safety and efficacy of ES-Cu-Captisol for Menkes disease. Reply. [PDF]
Gohil VM, Petris MJ, Palau F.
europepmc +1 more source
Concerns regarding the safety and efficacy of ES-Cu-Captisol for Menkes disease. [PDF]
Kaler SG.
europepmc +1 more source
FDA approval of copper histidinate (Zycubo) for Menkes disease: a therapeutic breakthrough in a rare pediatric neurodegenerative disorder. [PDF]
Ghani MH, Ahsan M, Raza AA, Samadi A.
europepmc +1 more source
Safety and efficacy of droxidopa for dysautonomia in adults with Menkes disease and occipital horn syndrome in the USA: a randomised phase 1/2a crossover trial. [PDF]
Kaler MM +10 more
europepmc +1 more source
Elesclomol-copper therapy improves neurodevelopment in two children with Menkes disease. [PDF]
Godoy-Molina E +31 more
europepmc +1 more source
Menkes disease is an X-linked disorder of copper metabolism. An overall copper deficiency reduces the activity of copper-dependent enzymes accounting for the clinical presentation of affected individuals.
Julian Mercer (13076475) +1 more
core
CRISPR prime editing as a promising therapeutic avenue for Menkes disease: the next step in correcting ATP7A mutations. [PDF]
Shahab SH, Habib F.
europepmc +1 more source
Retropseudogene insertion generated through retrotransposition in the <i>ATP7A</i> gene results in premature stop codons and a case of Menkes disease. [PDF]
Kou M, Ren B, Xing M, Chen L, Xu X.
europepmc +1 more source
Alpha-synuclein null mutation exacerbates the phenotype of a model of Menkes disease in female mice. [PDF]
Casey M +4 more
europepmc +1 more source

